PPD DEVELOPMENT LP
Entity uei:ZANENSW6C665 · UEI ZANENSW6C665 · parent: PPD DEVELOPMENT LP
Obligations by fiscal year
FY2024
$117.4M
Awards (1)
| 75A50124C00001↗ BARDA WILL IMPLEMENT A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER PHASE 2 TRIAL IN THE US TO EVALUATE THE SAFETY AND EFFICACY OF NOVEL HOST-DIRECTED THERAPEUTIC CANDIDATES IN HOSPITALIZED ADULTS WITH ARDS. | Department of Health and Human Services Office of Assistant Secretary for Preparedness and Response | FY2024 | Dec 15, 2023 – Sep 30, 2030 | $117.4M | $222.1M | 1 |
Observed spellings (1)
Raw recipient names from source records that resolved to this entity.
- PPD DEVELOPMENT LP
ZANENSW6C665· seen 2×